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Mycobacterium tuberculosis is one of the most notorious killers worldwide. These pathogens have evolved to infect human beings in 
a so-called dormant form that is extremely difficult to treat. New work, however, suggests that mycobacterial proteasomes, multi- 
component structures that protect the microbe from damaging effects of nitric oxide generated by the host, can be selectively and 
specifically blocked by small molecules. 
 
 
 
 
Mycobacterium tuberculosis is responsible 
for rv9 million new tuberculosis disease 
cases and over 2 million deaths annually. 
In the majority of infected individuals, the 
bacterium lies dormant and causes no 
immediate health problems. However, 
different environmental triggers (malnu- 
trition, deterioration of general health 
status and HIV infection) can reactivate 
the tubercle bacilli resulting in active 
tuberculosis. 
Upon infection via the airways, 
M. tuberculosis is internalized into alveolar 
macrophages that reside within the lung. 
Within these macrophages, phagocytosed 
M. tuberculosis resides within the so-
called mycobacterial phagosomes, 
thereby avoiding killing within lysosomal 
organelles through various strategies 
(Pieters, 2008). Macrophages harboring 
mycobacteria can remain within the lungs 
of the infected host or, alternatively, disse- 
minate to other organs in the body. In most 
healthy individuals, the immune defense 
system is well capable to control the infec- 
tion by M. tuberculosis such that disease 
cannot develop; in rv10% of the infected 
individuals, however, tuberculosis devel- 
ops with potential deadly outcome. One 
reason why healthy individuals are well 
able to control tuberculosis is because 
mycobacteria are being sequestered 
within granulomas, which are structures 
harboring macrophages infected with 
living tuberculosis within the center, sur- 
rounded by macrophages that are being 
 
kept in an activated state by surrounding 
T cells. Although the precise conditions 
within granulomas are still largely unde- 
fined, it is becoming clear that the granu- 
loma represents a balance in which M. 
tuberculosis is actively kept in check by 
macrophages and T cells (Cosma et al., 
2003). 
Several reasons exist why M. tuberculo- 
sis is such a difficult bacterium to eradi- 
cate. First, as mentioned, in many 
infected individuals, the bacilli are not 
actively replicating but are metabolically 
inactive causing a latent infection. 
Therefore, classical antibacterial agents 
that typically target growth and prolifer- 
ation pathways (DNA replication, gene 
transcription, protein translation and cell 
wall formation) fail miserably.  Secondly, 
M. tuberculosis is characterized by an 
especially thick and rigid cell wall, which 
makes it very difficult for compounds to 
access  the  mycobacterial  cell. Thirdly, 
M. tuberculosis, with a doubling time of 
rv18 – 22 h, is a very slowly growing organ- 
ism, resulting in frequent development of 
drug resistance, including multi and exten- 
sive drug resistance. On top of these strat- 
egies, M. tuberculosis has evolved highly 
successful strategies to avoid destruction 
within macrophage lysosomes, by actively 
blocking phagosome–lysosome fusion 
(Nguyen and Pieters, 2008). 
Given these obstacles, it is not surpris- 
ing that no drugs against tuberculosis 
have made it to the clinic in recent years. 
 
There is, however, some momentum gath- 
ering, in that several drug targets are being 
identified and analyzed for potential inhi- 
bition by small molecules (Butler, 2000; 
Warner and Mizrahi, 2007). One of these 
recently revealed drug targets is the myco- 
bacterial proteasome. 
Proteasomes are large multisubunit 
complexes that are primarily responsible 
for the proteolysis of cytoplasmic proteins. 
Proteasomes are present in virtually all 
organisms, highly conserved and essential 
in all eukaryotes. They consist of a core 
complex made up of four stacked rings, 
each made up of seven proteins (a and b 
subunits), giving the appearance of a 
barrel-like structure. Within the barrel, 
the central rings consist of seven pro- 
teases, with the active sites of these pro- 
teases oriented toward the center of the 
ring (Zwickl et al., 2001). This way, pro- 
teins can only be degraded at the inside 
of the barrel. In eukaryotes, targeting of 
proteasome substrates is coordinated by 
a regulatory particle or cap, which consists 
mainly of ATPases of the AAA family of pro- 
teins. Cytosolic proteins destined for pro- 
teasomal degradation are modified on 
lysine residues with ubiquitin, a small (76 
amino acid residues long) polypeptide. 
Proteins need to be modified with at 
least four ubiquitin molecules to be recog- 
nized by the proteasome. Such recognition 
occurs at the cap structure, by still poorly 
defined mechanisms, after which the 
protein is unfolded and translocated    to 
 
the inner core of the proteasome barrel 
where it is proteolysed by the active pro- 
teases present within the barrel. Small 
peptide fragments then leave the barrel 
again, and are further metabolized by as 
yet unknown processes. 
Although proteasomes are present in 
certain parasites, M. tuberculosis is thus 
far the only known bacterial pathogen pos- 
sessing proteasomes. The mycobacterial 
proteasomes seem to have a similar organ- 
ization  as  its  eukaryotic  counterpart.   
A function for the mycobacterial protea- 
some was revealed several years ago 
following a screen for mutant bacteria 
hypersensitive to acidified nitrite, such as 
present within mycobacterial phago- 
somes, in which M. tuberculosis is 
believed to survive and lie dormant. Of 
the several mutants that were identified, 
five contained insertions in genes coding 
for proteasome-associated molecules 
(Darwin et al., 2003), strongly implicating 
the mycobacterial proteasome in resist- 
ance to reactive nitrogen intermediates. 
Indeed, silencing of proteasome subunits 
results in an inability of M. tuberculosis 
to persist in mice (Gandotra et al., 2007). 
Therefore, it seems that mycobacterial pro- 
teasomes are involved in the resistance 
against nitric oxide-induced stress. 
Importantly, this work suggested that pro- 
teasomes are especially important during 
the dormant phase of M. tuberculosis, 
making the proteasome an attractive 
target for compounds that may interfere 
with dormant M. tuberculosis. 
The promise for proteasome inhibitors 
as potential drugs to treat tuberculosis 
has been dampened by the high degree 
of conservation of the mycobacterial pro- 
teasome with those from their mammalian 
host cells. Indeed, although proteasome 
inhibitors are currently being tested as 
agents against a variety of diseases, 
including cancer and neurodegenerative 
disorders (Huang and Chen, 2009), the 
idea of using proteasome inhibitors as 
anti-infectives has thus far been curbed 
because it has been impossible to 
develop proteasome inhibitors that avoid 
the inherent toxicity because of the impor- 
tant function for proteasomes in normal 
cellular homeostasis. 
In the current work, however, Lin et al. 
(2009) zoom in on a certain class of 
small  molecules,  the   oxathiazol-2-one 
compounds. Using an in vitro assay 
based on proteasome activity, Lin et al. 
screened 20 000 compounds and ident- 
ified two inhibitors of the oxathiazol-2-one 
class. These compounds permeated the 
mycobacterial cell wall, and were highly 
effective as inhibitors of M. tuberculosis 
growth in liquid cultures. Importantly, 
these inhibitors synergized with low 
amounts of nitric oxide in efficient killing 
of M. tuberculosis. 
As stated, one major disadvantage of all 
known proteasome inhibitors is their 
inherent toxicity due to blocking protea- 
some activity of the host. However, the 
oxathiazol-2-one compounds, although 
specifically and  irreversibly  inhibiting 
the   mycobacterial   proteasome,   were 
.1000-fold  less  effective  against  human 
proteasomes, and were inactive toward a 
series of different proteases, including 
trypsin, cathepsin B and metalloproteases. 
The biochemical analysis showed that 
the oxathiazol-2-one compounds modified 
the mycobacterial proteasome by covalent 
attack on the active site threonine (Thr 1) 
of the core complex b-subunit. As a result, 
Thr  1 undergoes cyclocarbonylation, 
thereby drastically modifying the environ- 
ment of the active site. With the knowledge 
of how the oxathiazol-2-one compounds 
modify the proteasome, the authors then 
used structural analysis to determine 
whether this modification can explain the 
exquisite specificity of the oxathiazol-2-one 
compounds toward mycobacterial protea- 
somes, although not affecting mammalian 
proteasomes. To that end, Lin et al. solved 
the structure of proteasome complexes, 
prior to and after exposure to oxathiazol- 
2-one compounds. This analysis first of all 
confirmed the modification of Thr 1 by the 
inhibitors, but also revealed another 
important consequence of modifying Thr1 
by oxathiazol-2-one  compounds. The 
substrate-binding pocket of the protea- 
some undergoes a major conformational 
change which involved several residues 
outside the active loop. According to the 
structural analysis, this newly formed 
moiety on Thr 1 causes an alternative 
protein confirmation in which the substrate- 
binding pocket is disturbed. Therefore, the 
substrates of mycobacterial proteasome 
fail to gain access to the proteasome result- 
ing in the accumulation of toxic   proteins 
and peptides within mycobacterial cells. 
Importantly, the substrate-binding 
pocket of human proteasomal b-subunits 
is speculated not to be changed by the 
modification of the oxathiazol-2-one com- 
pounds. The authors suggest that this is 
because the residues involved in maintain- 
ing the altered conformation are exten- 
sively non-conserved, and therefore not 
subject to inactivation through cyclocarbo- 
nylation (Lin et al., 2009). This of course 
allows  the  highly  selective  inhibition of 
M. tuberculosis proteasomes, without 
blocking host proteasomal activity. 
The irreversible inhibition of protea- 
somes by the oxathiazol-2-one com- 
pounds may prove to be of significant 
benefit under conditions where protein 
synthesis is drastically reduced, such as 
during dormancy, or blocked, such as is 
the case during antibiotic treatment. 
Indeed, as Lin et al. note, perhaps the 
most promising therapeutic options will 
consist of a combination of proteasome 
inhibitors with existing drugs that block 
protein synthesis at stages of transcrip- 
tion or translation. 
One of the most difficult issues in devel- 
oping drugs to combat tuberculosis is the 
fact that M. tuberculosis can adopt a 
dormant form that is virtually impossible 
to eradicate with existing treatments. 
Although there is presently no information 
of the effectiveness of oxathiazol-2-one 
compounds in an in vivo setting, the 
work by Lin et al. promises to provide 
desperately needed compounds  that 
can be developed into drugs to treat 
tuberculosis. 
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